Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $3.0 million.

  • SAB Biotherapeutics' Gains from Investment Securities rose 117.98% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 117.98%. This contributed to the annual value of $3.0 million for FY2024, which is 194.00% up from last year.
  • SAB Biotherapeutics' Gains from Investment Securities amounted to $3.0 million in FY2024, which was up 194.00% from $1.0 million recorded in FY2023.
  • SAB Biotherapeutics' 5-year Gains from Investment Securities high stood at $5.1 million for FY2021, and its period low was $709,470 during FY2022.
  • In the last 3 years, SAB Biotherapeutics' Gains from Investment Securities had a median value of $1.0 million in 2023 and averaged $1.6 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first slumped by 86.11% in 2022, then soared by 194.00% in 2024.
  • SAB Biotherapeutics' Gains from Investment Securities (Yearly) stood at $4.1 million in 2020, then increased by 24.52% to $5.1 million in 2021, then slumped by 86.11% to $709,470 in 2022, then spiked by 42.29% to $1.0 million in 2023, then spiked by 194.00% to $3.0 million in 2024.